Gladius Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Gladius Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,265	Closed	-$36.6K	–	413
2023 Q4	$36.6K	Buy	1,265 +310	+32%	+$8.22K	0.01%	232
2023 Q3	$26.3K	Buy	955 +240	+34%	+$7.31K	﹤0.01%	322
2023 Q2	$21.5K	Buy	+715	New	+$25K	﹤0.01%	299
2023 Q1	–	Sell	-1,019	Closed	-$36.3K	–	427
2022 Q4	$36.3K	Sell	1,019 -25	-2%	-$869	﹤0.01%	259
2022 Q3	$36K	Buy	+1,044	New	+$34K	﹤0.01%	248

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Gladius Capital Management's SUPN Position: Q1 2024 in Review

Gladius Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2024, closing a stake of 1,265 shares — an estimated $36.6K sold.

Gladius Capital Management first reported a position in SUPN in Q3 2022 and held it in 5 quarters. The position peaked at $36.6K in Q4 2023. 250 funds tracked by Wall St. Rank hold SUPN as of Q1 2024.

Gladius Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Gladius Capital Management sold 1,265 Supernus Pharmaceuticals shares in Q1 2024, an estimated $36.6K.
Gladius Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2022 and held it in 5 quarters.
Gladius Capital Management's Supernus Pharmaceuticals position peaked at $36.6K in Q4 2023.
250 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2024.

Based on Gladius Capital Management's 13F filing for Q1 2024, filed 14 May 2024.